| 1 | 1 | | 1 of 3 |
|---|
| 2 | 2 | | HOUSE DOCKET, NO. 393 FILED ON: 1/12/2023 |
|---|
| 3 | 3 | | HOUSE . . . . . . . . . . . . . . . No. 2182 |
|---|
| 4 | 4 | | The Commonwealth of Massachusetts |
|---|
| 5 | 5 | | _________________ |
|---|
| 6 | 6 | | PRESENTED BY: |
|---|
| 7 | 7 | | Carmine Lawrence Gentile and Hannah Kane |
|---|
| 8 | 8 | | _________________ |
|---|
| 9 | 9 | | To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General |
|---|
| 10 | 10 | | Court assembled: |
|---|
| 11 | 11 | | The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill: |
|---|
| 12 | 12 | | An Act to reduce incidence and death from pancreatic cancer. |
|---|
| 13 | 13 | | _______________ |
|---|
| 14 | 14 | | PETITION OF: |
|---|
| 15 | 15 | | NAME:DISTRICT/ADDRESS :DATE ADDED:Carmine Lawrence Gentile13th Middlesex1/12/2023Hannah Kane11th Worcester1/12/2023Lindsay N. Sabadosa1st Hampshire1/15/2023Marcus S. Vaughn9th Norfolk1/16/2023Angelo J. Puppolo, Jr.12th Hampden1/17/2023Kimberly N. Ferguson1st Worcester1/17/2023Susan Williams Gifford2nd Plymouth1/18/2023Natalie M. Blais1st Franklin1/18/2023Patricia A. Haddad5th Bristol1/18/2023Kathleen R. LaNatra12th Plymouth1/18/2023Joseph D. McKenna18th Worcester1/18/2023F. Jay Barrows1st Bristol1/18/2023Bradley H. Jones, Jr.20th Middlesex1/18/2023Steven Owens29th Middlesex1/18/2023Ryan C. FattmanWorcester and Hampden1/18/2023David K. Muradian, Jr.9th Worcester1/19/2023Vanna Howard17th Middlesex1/19/2023Christopher Hendricks11th Bristol1/19/2023 2 of 3 |
|---|
| 16 | 16 | | Christopher M. Markey9th Bristol1/19/2023Peter Capano11th Essex1/20/2023Steven S. Howitt4th Bristol1/20/2023Josh S. Cutler6th Plymouth1/20/2023Sean Garballey23rd Middlesex1/24/2023Patricia A. Duffy5th Hampden1/24/2023Brian W. Murray10th Worcester1/25/2023David F. DeCoste5th Plymouth1/25/2023Kate Hogan3rd Middlesex1/25/2023Kelly W. Pease4th Hampden1/26/2023Kate Donaghue19th Worcester1/27/2023Jack Patrick Lewis7th Middlesex1/30/2023Rodney M. Elliott16th Middlesex1/30/2023Brian M. Ashe2nd Hampden1/30/2023Paul K. Frost7th Worcester1/31/2023Michael P. Kushmerek3rd Worcester2/1/2023Antonio F. D. Cabral13th Bristol2/2/2023Thomas M. Stanley9th Middlesex2/2/2023Carole A. Fiola6th Bristol2/3/2023Paul A. Schmid, III8th Bristol2/3/2023Kevin G. Honan17th Suffolk2/3/2023Adrian C. Madaro1st Suffolk2/3/2023William M. Straus10th Bristol2/6/2023Carol A. Doherty3rd Bristol2/6/2023David Paul Linsky5th Middlesex2/7/2023Patrick Joseph Kearney4th Plymouth2/9/2023Alyson M. Sullivan-Almeida7th Plymouth2/9/2023David M. Rogers24th Middlesex2/10/2023Jessica Ann Giannino16th Suffolk2/12/2023Colleen M. Garry36th Middlesex2/13/2023Mike Connolly26th Middlesex2/13/2023Patrick M. O'ConnorFirst Plymouth and Norfolk2/13/2023Denise C. Garlick13th Norfolk2/15/2023Donald R. Berthiaume, Jr.5th Worcester2/15/2023Paul McMurtry11th Norfolk2/15/2023James B. EldridgeMiddlesex and Worcester2/18/2023Christopher Richard Flanagan1st Barnstable2/23/2023Natalie M. Higgins4th Worcester2/23/2023John Barrett, III1st Berkshire2/23/2023 3 of 3 |
|---|
| 17 | 17 | | Steven George Xiarhos5th Barnstable2/24/2023Angelo L. D'Emilia8th Plymouth2/24/2023Paul R. FeeneyBristol and Norfolk3/5/2023Jacob R. OliveiraHampden, Hampshire and Worcester3/10/2023Kate Lipper-Garabedian32nd Middlesex3/12/2023Tommy Vitolo15th Norfolk3/15/2023 1 of 5 |
|---|
| 18 | 18 | | HOUSE DOCKET, NO. 393 FILED ON: 1/12/2023 |
|---|
| 19 | 19 | | HOUSE . . . . . . . . . . . . . . . No. 2182 |
|---|
| 20 | 20 | | By Representatives Gentile of Sudbury and Kane of Shrewsbury, a petition (accompanied by |
|---|
| 21 | 21 | | bill, House, No. 2182) of Carmine Lawrence Gentile, Hannah Kane and others for legislation to |
|---|
| 22 | 22 | | reduce incidence and death from pancreatic cancer. Public Health. |
|---|
| 23 | 23 | | [SIMILAR MATTER FILED IN PREVIOUS SESSION |
|---|
| 24 | 24 | | SEE HOUSE, NO. 2304 OF 2021-2022.] |
|---|
| 25 | 25 | | The Commonwealth of Massachusetts |
|---|
| 26 | 26 | | _______________ |
|---|
| 27 | 27 | | In the One Hundred and Ninety-Third General Court |
|---|
| 28 | 28 | | (2023-2024) |
|---|
| 29 | 29 | | _______________ |
|---|
| 30 | 30 | | An Act to reduce incidence and death from pancreatic cancer. |
|---|
| 31 | 31 | | Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority |
|---|
| 32 | 32 | | of the same, as follows: |
|---|
| 33 | 33 | | 1 SECTION 1. Chapter 111 of the General Laws is hereby amended by adding the |
|---|
| 34 | 34 | | 2following section:- |
|---|
| 35 | 35 | | 3 Section 238. (a) The department shall administer a comprehensive pancreatic cancer |
|---|
| 36 | 36 | | 4initiative to provide coordinated pancreatic cancer prevention, screening, education and support |
|---|
| 37 | 37 | | 5programs in the commonwealth. The department may develop and implement other initiatives |
|---|
| 38 | 38 | | 6regarding pancreatic cancer awareness, research and care that the department determines will |
|---|
| 39 | 39 | | 7further the purposes of this section. |
|---|
| 40 | 40 | | 8 (b) There shall be a pancreatic cancer advisory council within the department. The |
|---|
| 41 | 41 | | 9council shall be appointed and convened by the commissioner and shall consist of 13 members 2 of 5 |
|---|
| 42 | 42 | | 10representing interdisciplinary fields including, but not limited to, oncology, palliative care, |
|---|
| 43 | 43 | | 11medicine, nursing, social work, pharmacy, spirituality and the area of patient and family |
|---|
| 44 | 44 | | 12caregiver advocacy, including health professionals having expertise treating pancreatic cancer |
|---|
| 45 | 45 | | 13patients and their families; provided, at least 1 member shall be a representative of the Pancreatic |
|---|
| 46 | 46 | | 14Cancer Action Network and 1 member shall be a representative of the American Cancer Society |
|---|
| 47 | 47 | | 15Cancer Action Network. The commissioner may appoint other members that the commissioner |
|---|
| 48 | 48 | | 16deems appropriate. Council members shall serve for a period of 3 years at the pleasure of the |
|---|
| 49 | 49 | | 17commissioner. The members shall elect a chair and vice chair whose duties shall be established |
|---|
| 50 | 50 | | 18by the council. The department shall provide a place for regular meetings of the council, which |
|---|
| 51 | 51 | | 19shall meet at least monthly. |
|---|
| 52 | 52 | | 20 Council members shall receive no compensation for their services but shall be allowed |
|---|
| 53 | 53 | | 21actual and necessary expenses in the performance of their council duties. |
|---|
| 54 | 54 | | 22 The council shall: |
|---|
| 55 | 55 | | 23 (1) Investigate and make recommendations for a system to certify and approve hospital |
|---|
| 56 | 56 | | 24systems that meet National Pancreatic Cancer Foundation criteria and post this information on an |
|---|
| 57 | 57 | | 25appropriate state website and on advocacy organization websites. |
|---|
| 58 | 58 | | 26 (2) Identify institutions and hospital systems which could meet the criteria in areas that |
|---|
| 59 | 59 | | 27are geographically underserved and provide them with incentives to develop the necessary |
|---|
| 60 | 60 | | 28resources to comply in order to assure that all residents have access to hospitals that meet the |
|---|
| 61 | 61 | | 29criteria. |
|---|
| 62 | 62 | | 30 (3) Investigate and make recommendations for the establishment of a multi-provider |
|---|
| 63 | 63 | | 31consortium to develop and disseminate amongst each other best practice algorithms, decision 3 of 5 |
|---|
| 64 | 64 | | 32aids for electronic health record systems, and quality metrics for all phases of care in pancreatic |
|---|
| 65 | 65 | | 33cancer. The consortium shall partner with other entities including, but not limited to, patient |
|---|
| 66 | 66 | | 34organizations, National Institute of Health and the American Cancer Society Cancer Action |
|---|
| 67 | 67 | | 35Network to develop and maintain a portfolio of statewide clinical trials in pancreatic cancer. |
|---|
| 68 | 68 | | 36 (4) Disseminate targeted communications to primary care providers and their office staff |
|---|
| 69 | 69 | | 37to connect them with the consortium members and resources which are local to their practices. |
|---|
| 70 | 70 | | 38 (5) Utilize the local resources of the consortium members to fully operationalize existing |
|---|
| 71 | 71 | | 39state initiatives to identify existing cancer support services, survivorship care and counseling and |
|---|
| 72 | 72 | | 40to expand these initiatives to meet current needs. |
|---|
| 73 | 73 | | 41 (6) Develop and support the use in all hospitals of a standard consent form for pancreatic |
|---|
| 74 | 74 | | 42cancer patients to consent to donate their tissue samples without restrictions for tissue collection |
|---|
| 75 | 75 | | 43and banking for research. |
|---|
| 76 | 76 | | 44 (b) The department, in conjunction with the pancreatic cancer advisory council, shall |
|---|
| 77 | 77 | | 45conduct a comprehensive study to ascertain the prevalence and incidence of pancreatic cancer in |
|---|
| 78 | 78 | | 46the commonwealth, the unmet needs of persons with pancreatic cancer and their families, time- |
|---|
| 79 | 79 | | 47of-diagnosis statistics and likely risks for pancreatic cancer. Information collected by the study |
|---|
| 80 | 80 | | 48shall include, but not be limited to, the following: |
|---|
| 81 | 81 | | 49 (1) germline testing results; |
|---|
| 82 | 82 | | 50 (2) molecular tumor analysis in patients with metastatic disease; |
|---|
| 83 | 83 | | 51 (3) hospitals treating the highest volume of pancreatic cancer patients; |
|---|
| 84 | 84 | | 52 (4) information on stage of diagnosis; 4 of 5 |
|---|
| 85 | 85 | | 53 (5) treatment rendered, including chemotherapy, radiation therapy, surgical treatment, |
|---|
| 86 | 86 | | 54neoadjuvant and adjuvant therapy; |
|---|
| 87 | 87 | | 55 (6) patient outcomes; |
|---|
| 88 | 88 | | 56 (7) number of patients diagnosed who did not receive any treatment or palliative care; |
|---|
| 89 | 89 | | 57and |
|---|
| 90 | 90 | | 58 (8) number of pancreatic resections performed at each hospital and associated outcomes. |
|---|
| 91 | 91 | | 59 (c) The department, in conjunction with the pancreatic cancer advisory council, shall |
|---|
| 92 | 92 | | 60develop and implement a statewide public education and community outreach program to inform |
|---|
| 93 | 93 | | 61the general public about genetic risks, signs, symptoms, and pre-malignant conditions associated |
|---|
| 94 | 94 | | 62with pancreatic cancer, including new-onset diabetes, and the availability of clinical trials for |
|---|
| 95 | 95 | | 63those with pancreatic cancer. In developing and implementing the program, the commissioner |
|---|
| 96 | 96 | | 64shall consult with similar programs including, but not limited to, anti-tobacco, obesity and other |
|---|
| 97 | 97 | | 65pre-malignant conditions associated with pancreatic cancer. The department shall add pancreatic |
|---|
| 98 | 98 | | 66cancer to the list of diseases that its programs target with counseling for tobacco discontinuation, |
|---|
| 99 | 99 | | 67diet and weight management. |
|---|
| 100 | 100 | | 68 SECTION 2. The commissioner of insurance shall survey health insurers in the |
|---|
| 101 | 101 | | 69commonwealth to ascertain coverage benefits of genetic testing for pancreatic cancer across |
|---|
| 102 | 102 | | 70health insurance plans, and present its findings to the committee on health care financing and the |
|---|
| 103 | 103 | | 71committee on financial services no later than June 30, 2022. |
|---|
| 104 | 104 | | 72 SECTION 3. The center for health information and analysis shall conduct a review and |
|---|
| 105 | 105 | | 73update of its mandated benefit review of pancreatic cancer screenings as reported in the center’s 5 of 5 |
|---|
| 106 | 106 | | 74report titled “Mandated Benefit Review of S.B. 471: An Act relative to pancreatic cancer |
|---|
| 107 | 107 | | 75screening,” dated July 2014, including an update of the cost analysis for pancreatic cancer |
|---|
| 108 | 108 | | 76screening for high-risk individuals. The center shall present its findings and update to the |
|---|
| 109 | 109 | | 77committee on health care financing and the committee on financial services no later than June |
|---|
| 110 | 110 | | 7830, 2022. |
|---|
| 111 | 111 | | 79 SECTION 4. The initial meeting of the pancreatic cancer advisory council shall convene |
|---|
| 112 | 112 | | 80no later than 60 days after the effective day of this act. |
|---|